Choroidal Alterations in Diabetic Macular Edema Treated with Intravitreal Dexamethasone: What Can Choroidal Vascularity Index Tell Us?
Source abstract
Abstract
Diabetes mellitus (DM) significantly impacts ocular health, particularly the retina and choroid, leading to diabetic retinopathy (DR) and diabetic macular edema (DME). This study aimed to evaluate the effects of intravitreal dexamethasone (IVD) on the choroidal vascularity index (CVI) in order to evaluate its potential as a biomarker. This was a retrospective observational study in which 37 eyes with DME treated with IVD were included. Baseline and follow-up (2 and 4 months post-injection) comprehensive ophthalmological examinations and spectral domain optical coherence tomography (SD-OCT) were performed. The CVI, luminal area (LA), stromal area (SA), and total area (TA) were assessed. No statistically significant changes in CVI, LA, SA, and TA were observed in the overall patient sample from baseline to 2 and 4 months post-IVD injection. However, a significant CVI reduction was noted in responder patients at 4 months. Positive correlations were found between the CVI and central macular thickness (CMT) at 2 months, suggesting that higher CMT values are associated with higher CVI values. This study indicated that IVD influences choroidal circulation, as evidenced by CVI reduction in responder patients. The CVI could potentially serve as an objective biomarker for treatment response in DME. Larger, prospective studies are warranted to clarify these findings further.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Retinal Diseases and Treatments · Retinal and Optic Conditions · Retinal Imaging and Analysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Ophthalmology Unit, Neurosciences, Mental Health, and Sensory Organs (NESMOS) Department, Sapienza University of Rome, 00189 Rome, Italy
St. Andrea Hospital, Via di Grottarossa 1035-1039, 00189 Rome, Italy
References (41)
Show source-provided references
1. Diabetes Mellitus, the Fastest Growing Global Public Health Concern: Early Detection Should Be Focused10.1002/hsr2.2004 ↗
2. Zhang, J., Zhang, J., Zhang, C., Zhang, J., Gu, L., Luo, D., and Qiu, Q. (2022). Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications. Cells, 11.10.3390/cells11213362 ↗
3. Viewing the Choroid: Where We Stand, Challenges and Contradictions in Diabetic Retinopathy and Diabetic Macular Oedema10.1111/aos.13210 ↗
4. Diabetic Choroidopathy10.1016/j.visres.2017.04.011 ↗
5. Scuderi, L., Fragiotta, S., Di Pippo, M., and Abdolrahimzadeh, S. (2023). The Role of Diabetic Choroidopathy in the Pathogenesis and Progression of Diabetic Retinopathy. Int. J. Mol. Sci., 24.10.3390/ijms241210167 ↗
6. Diabetic Choroidopathy. Light and Electron Microscopic Observations of Seven Cases10.1016/S0161-6420(85)34013-7 ↗
7. Relationship of Polymorphonuclear Leukocytes to Capillary Dropout in the Human Diabetic Choroid
8. Poly(l-Histidine)-Mediated On-Demand Therapeutic Delivery of Roughened Ceria Nanocages for Treatment of Chemical Eye Injury10.1002/advs.202302174 ↗
9. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA)10.1159/000458539 ↗
10. Dexamethasone Intravitreal Implant for Treatment of Diabetic Macular Edema in Vitrectomized Patients10.1097/IAE.0b013e318206d18c ↗
11. Treatment of Anti-Vascular Endothelial Growth Factor-Resistant Diabetic Macular Edema with Dexamethasone Intravitreal Implant10.1097/IAE.0b013e3182a48958 ↗
12. Optical Coherence Tomography Predictors of Favorable Functional Response in Naïve Diabetic Macular Edema Eyes Treated with Dexamethasone Implants as a First-Line Agent10.1155/2021/6639418 ↗
13. Macular and Peripapillary Choroidal Thickness in Diabetic Patients10.1097/IAE.0b013e31825db73d ↗
14. Choroidal Thickness in Patients with Diabetic Retinopathy10.2147/OPTH.S59395 ↗
15. Subfoveal Choroidal Thickness in Diabetes and Diabetic Retinopathy10.1016/j.ophtha.2013.03.009 ↗
16. Enhanced Depth Imaging Optical Coherence Tomography in Type 2 Diabetes10.1167/iovs.12-9692 ↗
17. Changes in Choroidal Thickness in Relation to the Severity of Retinopathy and Macular Edema in Type 2 Diabetic Patients10.1167/iovs.12-11503 ↗
18. Choroidal Thickness and Its Association with Age, Axial Length, and Refractive Error in Chinese Adults10.1167/iovs.63.2.34 ↗
19. The Choroidal Vascularity Index Versus Optical Coherence Tomography Angiography in the Evaluation of the Choroid with a Focus on Age-Related Macular Degeneration10.3390/tomography9040116 ↗
20. Luminal and Stromal Areas of Choroid Determined by Binarization Method of Optical Coherence Tomographic Images10.1016/j.ajo.2015.03.005 ↗
21. Choroidal Vascularity Index as a Measure of Vascular Status of the Choroid: Measurements in Healthy Eyes from a Population-Based Study10.1038/srep21090 ↗
22. Choroidal Thickness and Choroidal Vascularity Index Changes in Children with Type 1 Diabetes Mellitus without Retinopathy10.1016/j.pdpdt.2023.103706 ↗
23. Choroidal Vascularity Index in Patients with Type-1 Diabetes Mellitus without Diabetic Retinopathy10.1080/02713683.2020.1846755 ↗
24. GRAding of Functional and Anatomical Response to DExamethasone Implant in Patients with Diabetic Macular Edema: GRADE-DME Study10.1038/s41598-020-79288-w ↗
25. Alteration of Choroidal Vascular Structure in Diabetic Macular Edema10.1007/s00417-020-04604-z ↗
26. Choroidal Vascularity Index—A Novel Optical Coherence Tomography Parameter for Disease Monitoring in Diabetes Mellitus?10.1111/aos.13044 ↗
27. Characterisation of Choroidal Morphological and Vascular Features in Diabetes and Diabetic Retinopathy10.1136/bjophthalmol-2016-309366 ↗
28. Immunolocalization of Advanced Glycation End Products in Human Diabetic Eyes: An Immunohistochemical Study10.4236/jdm.2011.13009 ↗
29. Efficacy and Safety Profile of Intravitreal Dexamethasone Implant versus Antivascular Endothelial Growth Factor Treatment in Diabetic Macular Edema: A Systematic Review and Meta-Analysis10.1038/s41598-023-34673-z ↗
30. Intravitreal Ozurdex Has No Short Term Influence on Choroidal Thickness and Vascularity Index in Eyes with Diabetic Macular Edema: A Pilot Study10.4103/ojo.ojo_7_21 ↗
31. Short-Term Effects of Intravitreal Dexamethasone Implant on Choroidal Structure in Eyes with Refractory Diabetic Macular Edema10.14744/bej.2023.73644 ↗
32. Choroidal Vascularity Index after a Single Dose of Intravitreal Dexamethasone Implant in Patients with Refractory Diabetic Macular Oedema10.1016/j.pdpdt.2022.102996 ↗
33. Prognostic Value of Choroidal Vascular Index in Determining Response to Intravitreal Dexamethasone Implant Treatment Used in Refractory Diabetic Macular Edema10.1007/s10103-023-03711-7 ↗
34. Pharmacokinetics and Pharmacodynamics of a Sustained-Release Dexamethasone Intravitreal Implant10.1167/iovs.10-5285 ↗
35. The Effect of Intravitreal Anti-VEGF Injections on Choroidal Vascular Index in Patients with Diabetic Macular Edema10.1080/15569527.2024.2380325 ↗
36. Choroidal Vascularity Index as a Biomarker for Visual Response to Antivascular Endothelial Growth Factor Treatment in Diabetic Macular Edema10.1155/2021/3033219 ↗
37. Munk, M.R., Somfai, G.M., de Smet, M.D., Donati, G., Menke, M.N., Garweg, J.G., and Ceklic, L. (2022). The Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers. Int. J. Mol. Sci., 23.10.3390/ijms23147585 ↗
38. Associations of Serum Low-Density Lipoprotein and Systolic Blood Pressure Levels with Type 2 Diabetic Patients with and without Peripheral Neuropathy: Systemic Review, Meta-Analysis and Meta-Regression Analysis of Observational Studies10.1186/s12902-019-0453-5 ↗
39. Common Mechanisms Underlying Diabetic Vascular Complications: Focus on the Interaction of Metabolic Disorders, Immuno-Inflammation, and Endothelial Dysfunction10.1186/s12964-022-01016-w ↗
40. Choroidal Structural Changes and Choroidal Vascularity Index in Patients with Systemic Hypertension10.1177/11206721211035615 ↗
41. Choroidal Structural Alterations in Diabetic Patients in Association with Disease Duration, HbA1c Level, and Presence of Retinopathy10.1007/s10792-022-02363-w ↗